MarketCapExport financials
Kiniksa Pharmaceuticals, Ltd. (KNSA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Kiniksa Pharmaceuticals, Ltd. Balance Sheet 2025-2011 | KNSA
Brief overview of Kiniksa Pharmaceuticals, Ltd.'s balance sheet structure
The review uses the five latest available annual reports between 2021 and 2025.
Assets advanced +228% to $763.6 million from $232.8 million; annual growth near 34.6% reflects a fast increase in scale.
Liabilities grew faster than assets: +310.4% versus +228%. A substantial part of expansion was externally funded.
The equity-to-assets ratio is 74.3%, compared with 79.5% five periods ago. The balance sheet has a substantial internal cushion.
Net debt moved below zero to -$156.1 million, reflecting surplus cash over debt.
Cash accounts for 21.7% of assets versus 52.6% initially. The change indicates the degree of financial flexibility.
The accumulated result is -$462.1 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Balance sheet takeaway
Kiniksa Pharmaceuticals, Ltd. retains a reasonably healthy balance sheet structure, which still needs support from earnings and cash flow.
Annual Balance Sheet Kiniksa Pharmaceuticals, Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-156 M | -174 M | -95.7 M | -117 M | -116 M | -107 M | -46.9 M | -72 M | -45.6 M | -56 M | - | - | - | - | - |
Long Term Debt |
6.51 M | 7.86 M | 10 M | 2.62 M | 2.67 M | 4.88 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
2.99 M | 1.99 M | 2.25 M | 3.3 M | 3.38 M | 2.11 M | 1.7 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 1.28 M | 144 K | 120 M | 79.9 M | - | - | - | - | - |
Total Current Liabilities |
139 M | 101 M | 63.7 M | 47.1 M | 44.8 M | 31.8 M | 27.8 M | 42.6 M | - | - | - | - | - | - | - |
Total Liabilities |
196 M | 142 M | 87.5 M | 63.5 M | 47.8 M | 37.5 M | 29.1 M | 42.7 M | 137 M | 82.2 M | - | - | - | - | - |
Deferred Revenue |
- | - | 307 K | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-462 M | -521 M | -478 M | -492 M | -675 M | -517 M | -356 M | -194 M | -91 M | -26.1 M | - | - | - | - | - |
Total Assets |
764 M | 581 M | 526 M | 460 M | 233 M | 349 M | 255 M | 322 M | 47.5 M | 56.5 M | - | - | - | - | - |
Cash and Cash Equivalents |
166 M | 184 M | 108 M | 123 M | 122 M | 114 M | 46.9 M | 72 M | 45.7 M | - | - | - | - | - | - |
Book Value |
568 M | 438 M | 439 M | 396 M | 185 M | 312 M | 225 M | 279 M | -89.7 M | -25.7 M | - | - | - | - | - |
Total Shareholders Equity |
568 M | 438 M | 439 M | 396 M | 185 M | 312 M | 225 M | 279 M | -89.7 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Kiniksa Pharmaceuticals, Ltd.
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
5.86 M | 7.02 M | 7.24 M | 7.62 M | 8.56 M | 9.32 M | 9.86 M | 10.7 M | 11.3 M | 2.13 M | 2.62 M | 3.44 M | - | 2.1 M | 2.67 M | 3.5 M | 3.5 M | 4.2 M | 4.88 M | 4.88 M | 4.88 M | 4.88 M | 955 K | 955 K | 955 K | 955 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
220 M | 177 M | 166 M | 142 M | 118 M | 107 M | 87.8 M | 77.9 M | 72.7 M | 52.8 M | 63.5 M | 75.9 M | - | 64.7 M | 47.8 M | 38.8 M | 43.4 M | 40.5 M | 37.5 M | 37.5 M | 37.5 M | 37.5 M | 29.1 M | 29.1 M | 29.1 M | 29.1 M | 42.7 M | 42.7 M | 42.7 M | 42.7 M | 17.4 M | 17.4 M | 17.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | 12 K | 156 K | 2.56 M | 4.67 M | 6.5 M | - | 12.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-440 M | -476 M | -495 M | -513 M | -512 M | -500 M | -496 M | -503 M | -489 M | -504 M | -492 M | -496 M | - | -701 M | -675 M | -639 M | -609 M | -567 M | -517 M | -517 M | -517 M | -517 M | -356 M | -356 M | -356 M | -356 M | -194 M | -194 M | -194 M | -194 M | -91 M | -91 M | -91 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
825 M | 712 M | 661 M | 599 M | 555 M | 542 M | 520 M | 483 M | 484 M | 443 M | 460 M | 460 M | - | 231 M | 233 M | 253 M | 279 M | 311 M | 349 M | 349 M | 349 M | 349 M | 255 M | 255 M | 255 M | 255 M | 322 M | 322 M | 322 M | 322 M | 47.5 M | 47.5 M | 47.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
190 M | 175 M | 192 M | 157 M | 97.4 M | 99.3 M | 141 M | 118 M | 113 M | 80.6 M | 123 M | 176 M | 94.3 M | 63.3 M | 122 M | 190 M | 168 M | 120 M | 114 M | 114 M | 114 M | 114 M | 46.9 M | 46.9 M | 46.9 M | 46.9 M | 72 M | 72 M | 72 M | 72 M | 45.6 M | 45.6 M | 45.6 M | - | 56.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
606 M | 535 M | 495 M | 457 M | 437 M | 435 M | 432 M | 405 M | 412 M | 390 M | 396 M | 384 M | - | 166 M | 185 M | 214 M | 236 M | 271 M | 312 M | 312 M | 312 M | 312 M | 225 M | 225 M | 225 M | 225 M | 279 M | 279 M | 279 M | 279 M | 30.1 M | 30.1 M | 30.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
606 M | 535 M | 495 M | 457 M | 437 M | 435 M | 432 M | 405 M | 412 M | 390 M | 396 M | 384 M | 153 M | 166 M | 185 M | 214 M | 236 M | 271 M | 312 M | 312 M | 312 M | 312 M | 225 M | 225 M | 225 M | 225 M | 279 M | 279 M | 279 M | 279 M | -89.7 M | -89.7 M | -89.7 M | - | -25.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Kiniksa Pharmaceuticals, Ltd., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Irlanda
Israel
Britain
Schweiz
